Skip to content

Left Ventricular Physiological Effects of Veno-Arterial Extracorporeal Membrane Oxygenation Support During Cardiogenic Shock

Left Ventricular Physiological Effects of Veno-Arterial Extracorporeal Membrane Oxygenation Support During Cardiogenic Shock

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05426083
Enrollment
45
Registered
2022-06-21
Start date
2022-08-04
Completion date
2026-07-26
Last updated
2026-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome, Cardiogenic Shock

Keywords

Acute Coronary Syndrome, Cardiogenic Shock, Left ventricle, VA-ECMO

Brief summary

A Clinical Events Committee (CEC) will include Cardiac Surgery Professor and chief of cardiac surgery Rose Kelly MD, Professor of Medicine Ganesh Raveendran MD at the University of Minnesota who is the direction of Interventional Cardiology and Professor of Medicine at the University of Minnesota David Benditt. They will review and adjudicate serious and unexpected adverse events independently from the PI and co investigators.

Interventions

OTHERPhysiological Assessment

Observational only

Sponsors

University of Minnesota
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age 18-75 years * SCAI D/E CS requiring VA-ECMO support based on treating team's judgement. * MAP \>65 mmHg on \<3 vasopressors/inotropes at the time of consent * Cardiogenic shock due to acute coronary syndrome identified by coronary angiography at the index hospitalization per standard cardiology practice

Exclusion criteria

* VA-ECMO for sepsis, pulmonary embolism, COVID-19 related cardiorespiratory failure, severe RV failure due to severe idiopathic pulmonary hypertension * CS due to other (non-ACS) etiologies * Known patient with severe left ventricular dysfunction and stage IV NYHA heart failure being evaluated for or with a history of LVAD and transplantation prior to commencement of VA-ECMO * Profound vasoplegia with MAP \<65 mmHg on 3 vasopressors/inotropes * Moderate to severe aortic regurgitation (contraindication to VA-ECMO) * Moderate to severe aortic stenosis (contraindication to LV instrumentation with PV loop catheter) * Bleeding complications requiring ongoing transfusions of blood products * Ischemic lower extremities * Evidence of circuit thrombosis or fibrin accumulation (turndown increases risk for stroke and clot formation) * Evidence of sepsis or septic shock * Evidence of LV thrombus on echocardiography (contraindication for accessing LV cavity with catheters)

Design outcomes

Primary

MeasureTime frameDescription
Pressure-volume loops at the highest level of VA-ECMO support and the lowest level of VA-ECMO support.Day 3 of ECMOPressure-volume loops at the highest level of VA-ECMO support and the lowest level of VA-ECMO support.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORDemetris Yannopoulous, MD

University of Minnesota

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 21, 2026